Randomized Controlled Trial of a High Dose of Oral Erythromycin for the Treatment of Feeding Intolerance in Preterm InfantsMansi Y. · Abdelaziz N. · Ezzeldin Z. · Ibrahim R.
Department of Pediatrics, Faculty of Medicine, University of Cairo, Cairo, Egypt
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: To evaluate the effectiveness of high-dose erythromycin to treat feeding intolerance in preterm infants predominantly fed milk formula. Design: This study is a prospective randomized controlled trial on 60 premature infants suffering from feeding intolerance. Thirty infants were given oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days or until they reached full enteral feeds. Randomization was stratified according to gestational age <32 weeks or ≧32 weeks gestation. The primary end point was the time taken to establish full enteral feeding since enrollment. Potential adverse effects associated with erythromycin were also monitored. Student’s t test was used for comparison of continuous variables and χ2for categorical data. Results: In infants <32 weeks, the use of erythromycin was associated with more daily weight gain (12.8 ± 2.6 g vs. 9.2 ± 5.3 g, p = 0.04) compared to the control group. Time to reach full feed did not differ between the erythromycin (13.8 ± 3.9 days) and the control (17.46 ± 4.9 days) groups (p = 0.07). In infants ≧32 weeks, there were no differences between the erythromycin and the control groups. Conclusion: High-dose erythromycin is associated with greater weight gain in preterm infants <32 weeks gestational age, who are predominantly fed cow’s milk-based protein formulas.
© 2011 S. Karger AG, Basel
- Thureen P, Reynolds R: Special circumstances: trophic feeds, NEC, and BPD. Semin Fetal Neonatal Med 2007;12:64–70.
- Ng PC: Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants. Neonatology 2009;95:97–104.
- Kaufman SS, Gondolesi GE, Fishbein TM: Parentral nutrition associated liver disease. Semin Neonatol 2003;8:375–381.
Lander A, Redkar R, Nicholls G, et al: Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial. Arch Dis Child 1997;77:119–122.
- Curry JI, Lander TD, Stringer MD: Erythromycin as a prokinetic agent in infants and children. Aliment Pharmacol Ther 2001;15:595–603.
- Costalos C, Gounaris A, Varhalama E, Kokori F, Alexiou N, Kolovou E: Erythromycin as a prokinetic agent in preterm infants. J Pediatr Gastroenterol Nutr 2002;34:23–25.
- Nuntnarumit P, Kiatchoosakun P, Tantiprapa W, Boonkasidecha S: Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants. J Pediatr 2006;148:600–605.
- Aly H, Abdel-Hady H, Khashaba M, El-Badry N: Erythromycin and feeding intolerance in preterm infants: a randomized controlled trial. J Perinatol 2007;27:39–43.
- Ng PC, Gomez JM, Rajadurai VS, Saw S, Quak S: Establishing enteral feeding in preterm infants with feeding intolerance; a randomized controlled trial of low dose erythromycin. J Pediatr Gastroentrol Nutr 2003;37:554–558.
- Ng PC, So KW, Fung KS, Lee CH, Fok TF, Wong E, et al: Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001;84:F177–F182.
- Ng PC, Lee CH, Wong SP, Lam HS, Liu FYB, So KW, Lee CY, Fok TF: High dose oral erythromycin decreased the incidence of parentral nutrition-associated cholestasis in preterm infants. Gastroenterology 2007;132:1726–1739.
- Cairns PA, Craig S, Tubman R, Roberts RS, Wilson J, Schmidt B: Randomised controlled trial of low dose erythromycin in preterm infants with feed intolerance. Pediatr Res 2002;51:379A.
- El Hennawy AA, Sparks J W, Armentrout D, Huseby V, Berseth CL: Erythromycin fails to improve feeding outcome in feeding intolerant preterm infants. J Pediatr Gastroentrol Nutr 2003;37:281–286.
Madani A, Pishva N, Pourarian Sh, Zarkesh M: The efficacy of oral erythromycin in enhancement of milk tolerance in premature infants. A randomized controlled trial. Iran J Med Sci 2004;29:1–4.
- Oei J, Lui K: A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants. Acta Paediatr 2001;90:904–908
- Jadcherla SR, Klee G, Berseth CL: Regulation of migrating motor complexes by motilin and pancreatic peptide in human infants. Pediatr Res 1997;42:365–369.
- Coulie B, Tack J, Peeters T, Janssen J: Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998;43:395–400.
- Varanness BD, Parys V, Ropert A, Chayvialle JA, Roze C, Galmiche JP: Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995;109:32–39.
- Annese V, Janssens J, Vantrappen G, Tack J, Peeters TL, Willemse P, Van Cutsem E: Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992:102:823–828.
- Tack J,Vantrappen G, Peeters T, Annese V, Depoortere I, Muls E, Janssens J, Bouillon R: Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992;103:72–79.
Bisset WM, Watt J B, Rivers PA, Milla PJ: Ontogeny of fasting small intestinal motor activity in the human infant. Gut 1998;29:483–488.
- Berseth CL: Gestational evolution of small intestinal motility in preterm and term infa nts. J Pediatr 1989;115:646–651.
- Vantrappen GR, Janssens J, Peeters TL, Bioom SR, Christofides ND, Hellemans J: Motilin and the interdigestive motor complex in man. Dig Dis Sci 1979;24:497–500.
- Tomomasa T, Tabata M, Nako Y, Kaneko H, Morikawa A: The effect of oral erythromycin on gastric emptying in neonates with gastric retention. Gastroenterology 1997;112(suppl):A839.
- Jadcherla SR, Berseth CL: Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr 2002;34:16–22.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.